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Abstract  
Aims 
To assess the effectiveness of brief interventions in primary care aimed at reducing or 
discontinuing long-term benzodiazepine/Z-drug (BZRA) use. 
Method 
Systematic review of randomised controlled trials of brief interventions in primary care settings 
aimed at reducing or discontinuing long-term BZRA use in adults taking BZRAs for ≥3 
months. Four electronic databases were searched: PubMed, EMBASE, PsycINFO, CENTRAL. 
The primary outcome was BZRA use, classified as discontinuation or reduction by ≥25%. The 
Theoretical Domains Framework (TDF) was used to retrospectively code behavioural 
determinants targeted by the interventions. The Behaviour Change Technique (BCT) 
Taxonomy was used to identify interventions’ active components. Study-specific estimates 
were pooled, where appropriate, to yield summary risk ratios (RRs) and 95% confidence 
intervals (CIs). Pearson correlations were used to determine the relationship between 
intervention effect size and the results of both the TDF and BCT coding.  
Results 
Eight studies were included (n=2071 patients). Compared with usual care, intervention patients 
were more likely to have discontinued BZRA use at 6 months (8 studies, RR 2.73, 95% CI 
1.84-4.06) and 12 months post-intervention (2 studies, RR 3.41, 95% CI 2.22-5.25). TDF 
domains ‘Knowledge’, ‘Memory, attention and decision processes’, ‘Environmental context 
and resources’ and ‘Social influences’ were identified as having been included in every 
intervention. Commonly identified BCTs included ‘Information about health consequences’, 
‘Credible source’ and ‘Adding objects to the environment’. There was no detectable 
relationship between effect size and the results of either the TDF or BCT coding.   
Conclusion 
Brief interventions delivered in primary care are more effective than usual care in reducing and 
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Introduction  
Benzodiazepines have multiple clinical indications, including anxiety and insomnia. 
Guidelines recommend restricting benzodiazepine prescriptions to short-term use (≤4 weeks) 
to minimise adverse outcomes, such as dependence and withdrawal symptoms (1, 2). Similar 
recommendations apply to Z-drugs (e.g. zopiclone, zolpidem), a group of non-benzodiazepine 
hypnotics which are also available to treat insomnia (3). However, guidelines are often not 
adhered to as long-term use of these medications, which are collectively referred to as 
benzodiazepine receptor agonists (BZRAs), persists worldwide (4, 5). Numerous countries 
have reported no notable changes, or only modest decreases, in benzodiazepine use in recent 
years (6-9). In some instances, changes in benzodiazepine prescribing have been offset by 
increased Z-drug prescribing (5, 9-11) for which evidence of a more favourable risk profile is 
lacking (3).  
The estimated prevalence of long-term BZRA use (>6 months) among the general population 
varies across countries (range 6-15%) with the highest prevalence reported among older people 
(range 22-55%) who are typically defined as ≥65 years (12-14). Long-term benzodiazepine use 
is one of the most commonly identified indicators of potentially inappropriate prescribing in 
older people (15-20). This is concerning as age-related physiological changes impact on the 
drugs’ pharmacokinetics and pharmacodynamics, thereby, making older adults most 
susceptible to BZRAs’ adverse effects such as falls, fractures and cognitive impairment (21, 
22). Only in recent years have prescribing tools to assess quality use of medicines incorporated 
Z-drugs (e.g. Beers criteria (23)). Hence, comparatively fewer studies have examined 
potentially inappropriate Z-drug prescribing and associated risks (24, 25). The ongoing issue 
of long-term BZRA use has called existing guidelines into question (26). As long-term BZRA 
prescribing also occurs in middle-aged populations (typically defined as 45-64 years) (7, 27), 
the problem is likely to persist for generations to come without targeted interventions.  
Various interventions aimed at discontinuing long-term benzodiazepine use have been 
evaluated and, in recent years, efforts have been made to systematically review and pool 
existing evidence (28-32). However, previous research has largely overlooked Z-drugs. 
Previously evaluated interventions range from brief interventions (i.e. written letters, self-help 
information, or short consultations with healthcare professionals directed towards the specific 
goal of reducing or discontinuing patients’ long-term use of the medication) to more complex 
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interventions involving cognitive behavioural therapy (CBT) and pharmacological treatment 
(e.g. anticonvulsants) (28-31).  
An existing Cochrane review on interventions targeting benzodiazepine dependence and abuse 
specifically highlighted brief interventions as an area warranting further research (33). Brief 
interventions have been described as a family of interventions which can be directed at different 
target groups and vary in length, structure, media of communication and personnel responsible 
for their delivery (34). Brief interventions have been extensively reviewed in the context of 
alcohol use (35) and defined as “in-person, time-limited efforts to provide information or 
advice, increase motivation to avoid substance use, or to teach behaviour change skills with the 
aim of reducing substance use and the likelihood of experiencing negative consequences” (36). 
Brief interventions are applicable in targeting long-term BZRA use. For example, the stepped 
care approach (Supporting Information, S1), which was developed for treating benzodiazepine 
dependence, advocates for brief intervention-based approaches before progressing to more 
intensive interventions (e.g. CBT) if required (37). However, a number of previous related 
reviews have not explicitly defined the concept of a brief intervention as it applies to long-term 
BZRA use or elaborated on the intervention’s core components beyond the information that 
was outlined to patients about BZRAs and whether the interventions were provided in person 
(e.g. short consultations) or through written communication (e.g. letters advising patients to 
reconsider their long-term use of the medication) (29-31). 
Despite evidence of effectiveness for some existing intervention approaches, a lack of 
theoretical underpinning has been identified in this field of research (38). This limits our 
understanding of the causal mechanisms underlying the interventions’ effects. To address this, 
determinants of the target behaviour (i.e. long-term BZRA use) need to be examined, together 
with the interventions’ active components.  
The Theoretical Domains Framework (TDF) can be used to identify the determinants of the 
target behaviour (39). The TDF distils psychological theory relevant to behaviour change into 
theoretical domains which are considered to be mediators (i.e. barriers and facilitators) of 
behaviour change (40, 41). Identifying key mediators involved in changing target behaviours 
provides a theoretical basis for informing a rigorous and systematic intervention development 
process (42). In cases where intervention development is not based on explicit theories, it is 
likely that intervention developers nevertheless had an implicit idea of how change was to 
occur that informed the implicit mediators they targeted. It is therefore possible to 
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retrospectively identify and code factors (or in this case, domains) that interventions may have 
targeted using a sufficiently broad framework such as the TDF (43). This can help to understand 
the behavioural determinants targeted in order for an intervention to elicit behaviour change 
and can contribute to a cumulative evidence base for designing future interventions (43).  
It is also possible to identify and describe interventions’ active components using standardised 
terminology. For example, the Behaviour Change Technique taxonomy (version 1, BCTTv1) 
(44), consists of 93 BCTs and has been applied in a number of systematic reviews to help 
identify component BCTs of interventions and to explore their impact on effectiveness (45-
47). Applying the taxonomy in this way can facilitate intervention replication and evidence 
synthesis (47). 
Aim and objectives  
A systematic review was undertaken which aimed to evaluate the evidence-base for brief 
interventions targeting long-term BZRA use in primary care settings.  
The objectives were to: 
1. Examine the effectiveness of brief interventions targeting long-term BZRA use in primary 
care in terms of the pre-determined primary and secondary outcomes.  
2. Assess risk of bias (including publication bias). 
3. Assess reporting of intervention development and evaluation in published manuscripts. 
4. Explore behavioural determinants targeted by the interventions using the TDF (41).  
5. Identify BCTs present in the interventions using the BCTTv1 (44).  
 
Methods  
A systematic review was conducted of randomised controlled trials (RCTs), including cluster 
RCTs (cRCTs), evaluating brief interventions targeting long-term BZRA use in primary care 
settings (e.g. general practice, community pharmacy) against usual care. The primary research 
question and analysis plan were not pre-registered on a publicly available platform. For the 
purpose of this review, a brief intervention was defined as an intervention comprising oral or 
written communication that involved discussion, negotiation or encouragement for reduction 
or discontinuation of long-term BZRA use, with or without additional support or follow-up. 
This definition was adapted from the National Institute of Health and Care Excellence (48). As 
brief interventions are considered time-limited efforts to deliver information and promote 
behaviour change (36), eligible interventions had to be delivered in the context of routine 
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clinical consultations (i.e. for interventions involving face-to-face consultations) and/or with 
minimal impact on routine clinical practice (i.e. for interventions involving written information 
sent directly to patients). It was anticipated that some interventions would include advice on 
gradual dosage reduction strategies and, therefore, no limit was set on the number of additional 
follow-up consultations. 
Interventions were eligible for inclusion if they were directed at changing patients’ long-term 
BZRA use behaviour, delivered within or through primary care settings, and specifically 
targeted adult patients (≥18 years) prescribed BZRAs on a long-term basis. There is no 
consensus as to the duration that constitutes long-term BZRA use (13). Therefore, study 
definitions of long-term use were accepted provided that the mean (or median) duration was at 
least three months which is consistent with previous related reviews (29-31). Interventions 
focussing on CBT were excluded, as were interventions targeting long-term BZRA use as part 
of a wider initiative to address potentially inappropriate prescribing. This review was 
conducted and reported in line with the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines (Supporting Information, S2) (49).  
The primary outcome was BZRA use and was classified as either complete discontinuation or 
reduction by ≥25%. There is no established threshold for a clinically significant BZRA dosage 
reduction. Previous studies have arbitrarily defined reduction using thresholds ranging between 
25-50% (50, 51). It has been suggested that a trial dosage reduction, without an obligation to 
completely stop the medication, may enhance motivation among patients who are reluctant to 
consider a change to their current BZRA use (52). For the purpose of this review, dosage 
reduction was defined as ≥25% to provide a threshold that may have described a meaningful 
reduction in patients’ BZRA use as opposed to a random fluctuation. Secondary outcomes 
comprised: health-related quality of life; withdrawal symptoms; anxiety; sleep quality; 
depression; and healthcare utilisation (i.e. GP visits, hospital admissions, use of other 
medications). 
Search strategy and data extraction 
The following electronic databases were searched from inception to February 2019: PubMed, 
EMBASE, PsycINFO and CENTRAL. The search strategy (Supporting Information, S3) was 
developed with assistance from a research librarian using relevant keywords and medical 
subject heading (MeSH) terms. These included: benzodiazepines, Z-drugs, brief intervention, 
withdrawal, reduction and discontinuation. Validated sensitivity-maximising filters were 
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applied (53). Abstracts were screened for inclusion by two authors (TL, CC) working 
independently. If studies appeared to meet inclusion criteria, full-text articles were retrieved 
and assessed for inclusion. Searches were restricted to English language publications. 
Conference abstracts were not included. Any disagreements were resolved by discussion 
between authors and consultation with a third author (CR) if necessary. 
Data extraction was performed independently by two authors (TL, CC) using a purposefully-
designed data extraction form which was piloted on one of the included studies.  Data were 
extracted relating to study design, participants, interventions, control groups and outcomes. 
Information was also extracted in relation to included studies’ risk of bias using the Cochrane 
Collaboration’s risk of bias tool (54). The reporting of intervention development and evaluation 
was assessed using the Workgroup for Intervention Development and Evaluation Research 
(WIDER) checklist (55, 56). Inconsistencies were resolved by discussion between authors. 
 
Analysis 
Primary outcome data from individual studies were combined through meta-analysis where 
possible (comparable interventions and outcomes) by calculating the risk ratio (RR) and 95% 
confidence interval (CI) using a random-effects model. For studies that assessed more than one 
brief intervention, intervention group outcome data were pooled where the intervention groups 
involved modest variations of the core brief intervention (as evidenced by the findings of the 
BCT coding exercise outlined below) and no detectable differences were observed between the 
different forms/variations of the brief interventions for outcome assessments relating to BZRA 
use. This allowed one single comparison against the control arm as recommended in the 
Cochrane Handbook (57). For each of the cRCTs, results were adjusted for clustering using the 
study’s reported intra‐class correlation coefficient to calculate the effective sample size based 
on the recommended methods outlined in the Cochrane Handbook (58). The Cochrane 
Handbook’s definitions of heterogeneity were used to assist interpretation: potentially not 
important (I2=0%-40%), moderate (I2=30%-60%), substantial (I2=50%-90%) and considerable 
heterogeneity (I2=75%-100%) (59). If outcome data could not be pooled, a narrative summary 
was provided. Funnel plots were to be used to assess publication bias if comparable data were 
available from at least 10 studies (60). 
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Intervention coding  
The behavioural determinants that interventions may have targeted were explored using the 
TDF following established methods (43), as summarised below. Verbatim descriptions of 
intervention and control groups were extracted. Study authors were emailed to verify the 
reported descriptions and asked for any additional supporting information. Intervention and 
control groups were coded using the 14 domains from TDF version 2 (41) as the coding 
framework. A coding manual was developed by the research team which included established 
definitions of each domain (41) together with examples of items to code under each domain 
(Supporting Information, S4). The coding manual was developed using a sample of brief 
intervention studies included in previous related reviews (29-31). All TDF coding was 
conducted independently by two members of the research team (TL, CC). Any inconsistencies 
were resolved by discussion and consultation with a third reviewer (CR). 
Pearson correlations (two-tailed) were used to determine the relationship between the 
intervention effect size for the primary review outcomes and the number of different domains 
coded (maximum score of 14). For three-armed studies involving more than one brief 
intervention, the average number domains coded across intervention groups was used. Coding 
of domains in the control groups was subtracted from coding of domains in the intervention 
groups. A sensitivity analysis was subsequently performed in which the coding in the control 
groups was not subtracted. 
BCTs included in the interventions were explored using the BCTTv1 (44) based on the method 
previously described by Presseau et al. (47) and using the same extracted information for the 
TDF analysis. Preliminary coding was conducted by two members of the research team (CC, 
ZvA) using the entire taxonomy. Based on the results of this analysis, a coding manual was 
developed which included established definitions for the subset of identified BCTs and 
examples of items to code under each BCT (Supporting Information, S5). BCT coding was 
then conducted independently by two members of the research team (TL, CC) using the coding 
manual. Any inconsistencies were resolved by discussion and consultation with a third 
reviewer (ZvA). Pearson correlations were used to determine the relationship between the 
number of different BCTs coded and intervention effect size for the primary review outcomes. 
 
 
This article is protected by copyright. All rights reserved. 
Results  
Results of the search 
Figure 1 summarises the search results. Six RCTs (50, 61-65) and two cRCTs (66, 67) were 
included, four of which were three-armed trials that compared different types of brief 
interventions against usual care (50, 62, 64, 67). In total, 2071 patients were involved, most of 
whom were female (71.2%). Participants’ mean age ranged from 59-75 years. Only two studies 
reported that patients were prescribed Z-drugs (64, 67). The studies were conducted in general 
practice (50, 61-63, 67), integrated healthcare delivery systems (64, 65) and community 
pharmacies (66) across four countries: Canada (66), Spain (63, 67), UK (50, 61, 62) and USA 
(64, 65). 
Description of the interventions 
Table 1 provides an overview of each intervention which consisted primarily of written letters 
signed by patients’ prescribers or a clinical pharmacist and short consultations provided by 
healthcare professionals (GPs, practice pharmacists, practice nurses) recommending 
reduction/discontinuation of the medications. One study used a patient empowerment-based 
educational resource consisting of a personalised booklet that was posted to patients (66). The 
booklet contained a self-assessment detailing risks of benzodiazepine use and knowledge 
statements designed to create cognitive dissonance about the perceived safety of 
benzodiazepine use. A peer champion story was also included that was designed to encourage 
participants to attempt discontinuation using the included GDR protocol. 
All interventions advocated gradual dose reduction (GDR) to patients. However, the guidance 
provided on GDR varied. For example, in some studies patients were given general advice on 
GDR (e.g. by taking the medication only when needed (62) or by taking half a tablet as opposed 
to a full one (50)). In other studies, more detailed tapering schedules were provided. In a 
number of studies, interventions were supplemented with additional consultations, telephone 
calls and written educational resources (e.g. information sheets, self-help booklets). 
 
Primary outcomes 
Pooled data from all eight studies (1168  intervention participants, 796  control participants) 
showed that intervention participants were more likely to discontinue BZRA use six months’ 
post-intervention compared to control group participants (RR 2.73, 95% CI 1.84-4.06) (Figure 
2). Moderate heterogeneity was observed across studies (I2 =55%, P=0.03). 
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Pooled data from two studies (63, 67) (376 intervention participants, 212 control participants) 
showed that intervention participants were more likely to discontinue BZRA use 12 months’ 
post-intervention compared to control group participants (RR 3.41, 95% CI 2.22-5.25) (Figure 
3). Potentially unimportant heterogeneity was observed across studies (I2 =18%, P=0.27). 
Reduction in BZRA use 
Pooled outcome data from five studies (50, 61, 62, 65, 66) (692 intervention participants, 534 
control participants) showed that intervention participants were more likely to reduce 
benzodiazepine use six months’ post-intervention compared to control group participants (RR 
1.68, 95% CI 1.03, 2.75) (Figure 4). Considerable heterogeneity was observed across studies 
(I2 =63%, P=0.03). No study included in this meta-analysis involved Z-drug patients. 
Only one study (63) reported reduction of BZRA  use at 12 months’ post-intervention, 
therefore, meta-analysis was not possible. The study showed that 16 (21.9%) intervention 
participants reduced BZRA compared with 11 (16.7%) control group participants.  
Secondary outcomes 
An outline of secondary outcomes reported across included studies together with an overview 
of the assessment tools that were used is provided in Supporting Information, S6-7. Due to 
differences in the assessment and reporting of secondary outcomes, meta‐analysis was not 
possible. Limited reported data for secondary outcome assessments across studies also made it 
difficult to provide a narrative summary of results. For example, both studies that reported 
assessments of anxiety used different assessment scales: the Hospital Anxiety and Depression 
Scale (63) and Part B of the General Health Questionnaire (50). Outcome data were not clearly 
reported for one of the studies (50) which precluded any meaningful synthesis. 
Risk of bias  
The risk of bias assessments are shown in Figure 5. Only two studies showed a low risk of bias 
across most domains. Four studies were at high risk of contamination bias (‘other bias’) 
whereby those delivering the intervention also cared for control group participants.  
Publication bias 
Given that fewer than 10 studies were included in each meta-analysis, assessments of funnel 
plot asymmetry were not conducted because the power of the statistical tests was too low to 
distinguish real asymmetry from chance (60). 
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Intervention development and evaluation in published manuscripts  
Table 2 shows the results of the WIDER checklist assessment. Most studies outlined the mode 
of delivery (n=6) and characteristics of intervention recipients (n=7). Four studies provided 
detailed descriptions of the intervention and content delivered. Only one study (66) described 
intervention development and referred to the use of formal theory which included social 
constructivist learning theory and self-efficacy theory. 
Two studies published study protocols with one also including an intervention manual. None 
of the studies provided detailed descriptions of control conditions. One study identified an 
unexpected deviation from the protocol whereby a practice pharmacist and a nurse delivered 
interventions instead of the GP (50).  
Barriers and enablers targeted and behaviour change techniques identified 
Twelve theoretical domains were identified as being targeted across the interventions (Table 
3). The total number of domains identified per intervention varied (range 6-11). ‘Knowledge’, 
‘Memory, attention and decision processes’, ‘Environmental context and resources’ and 
‘Social influences’ were identified in every intervention. The only domains that were not 
evident in interventions were ‘Emotion’ and ‘Social/Professional role and identity’.  
There was no detectable relationship between intervention effect size for BZRA 
discontinuation or reduction at six months and the number of different domains coded (Table 
4). A sensitivity analysis (whereby control group domains were not subtracted) showed similar 
results.  
Seventeen BCTs were identified across the studies (Table 5). The number of BCTs per 
intervention varied (range 4-8). The most commonly identified BCTs were ‘Information about 
health consequences’, ‘Credible source’ and ‘Adding objects to the environment’. No 
detectable relationship was found between intervention effect size for BZRA discontinuation 
or reduction at six months post-intervention and the number of identified BCTs (Table 6).  
Insufficient numbers of studies reported on discontinuation and reduction at 12 months’ post-
intervention to allow correlation between effect size and the results of the TDF and BCT coding 
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Discussion  
This review identified eight studies that evaluated brief interventions targeting long-term 
BZRA use in primary care (50, 61-67). The pooled effect estimates showed that, compared to 
usual care, patients who received a brief intervention were more likely to reduce or discontinue 
long-term BZRA use at six and 12 months’ post-intervention. This is consistent with previous 
related reviews (29-31). The review offers support for the first stage of the aforementioned 
‘stepped care’ approach (37). The additional assessments undertaken through application of 
the WIDER checklist (55) and intervention coding involving the TDF (41) and BCTTv1 (44), 
have provided detailed insight into intervention content, development and reporting that has, 
to date, been lacking. For example, a scoping review of interventions targeting discontinuation 
of long-term BZRA use among community-dwelling adults by Pollman et al. (38) applied the 
Behaviour Change Wheel to identify broad categorisations of intervention functions (e.g. 
enablement, training) (68). Given its scoping nature, the review included a broader range of 
interventions and study designs than the current review and did not look to pool outcome data 
across included studies. The identified intervention functions did not provide insights into the 
behavioural determinants that were targeted by the interventions or the specific BCTs that were 
used to elicit behaviour change. The TDF and BCT coding exercises in the current review have 
helped to address this. Pollman et al. (38) also reported that intervention reporting was poor 
across included studies. However, as no specific reporting tool was applied to the study reports, 
it was not possible to identify which specific aspects of intervention reporting needed to be 
improved. The application of the WIDER checklist in the current review has helped to address 
this. The current review advances this previous work and will help to build a more cumulative 
and replicable evidence base. 
A variety of brief interventions were evaluated comprising discontinuation letters, short 
consultations with healthcare professionals and written educational information, delivered 
alone or in combination. The WIDER assessments (55) showed that intervention development 
was often poorly described. In recent years, the UK Medical Research Council’s complex 
intervention framework (69) has drawn considerable attention to intervention development and 
evaluation processes. The framework advocates using evidence and theory during intervention 
development to inform selection of relevant components, prior to feasibility testing. This 
precedes definitive evaluations of intervention effectiveness. Although a number of studies had 
considered existing evidence by adapting interventions from previous research, the role of 
theory was largely overlooked whereby only one study reported incorporating theory into the 
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intervention development process (66). A realist evaluation that was conducted alongside the 
main trial of this intervention enabled the researchers to investigate the mechanisms and 
contexts underlying its effects from patients’ perspectives (70). This evaluation found that 
targeting patients’ motivation and capacity to discontinue BZRAs yielded successful outcomes 
where healthcare providers were supportive, and patients did not have internal competing 
desires to continue BZRA use. These findings helped to refine the initial theoretical 
understanding of how the intervention worked and provided important insights that could help 
to inform implementation of such interventions on a wider scale. The lack of underpinning 
theory across the other included studies limits our understanding of why the interventions were 
successful and how they exerted their effects (71).  
In addition to considering intervention development processes, it is also important to examine 
their content and delivery. All included studies recommended GDR, however, the specific 
instructions provided to patients varied. For example, patients were advised to reduce their 
benzodiazepine use by taking the medication only when needed (62) or by taking half a tablet 
as opposed to a full one (50). These suggestions could prompt overly rapid dosage reductions 
(e.g. reduction by 50% or even abrupt discontinuation) which could precipitate withdrawal 
symptoms and hinder patients’ success in discontinuing long-term use. GDR regimens vary in 
the literature and an optimal GDR schedule has yet to be identified (22, 29). Therefore, a 
personalised and flexible approach is preferable which allows patients to balance dosage 
reduction against the emergence of any withdrawal symptoms (22). The extent to which 
benzodiazepine-related GDR processes are transferrable to Z-drugs has previously been 
questioned (38). However, the findings of the single study that specifically targeted Z-drug 
patients indicate that personalised GDR regimens are also helpful to this patient cohort (64).  
The included studies highlighted the potential to include healthcare professionals other than 
prescribers in intervention delivery (e.g. pharmacists (50, 64, 65)). A follow-up evaluation of 
the study by Heather et al. that identified a deviation from trial protocol, whereby a practice 
pharmacist had delivered interventions instead of the GP, found the pharmacist’s involvement 
to be a potentially cost-effective means of reducing long-term benzodiazepine use (72). This 
warrants further investigation and could help in maximising efficiency of intervention delivery. 
Outcome evaluations were generally limited to six and 12 months’ post-intervention. One study 
reported that approximately 70% of patients that discontinued BZRAs at 12 months’ post-
intervention maintained this at 36 months’ follow-up (73). This is a positive finding in relation 
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to the interventions’ long-term effects. Furthermore, a follow-up study of a non-RCT 
evaluation of a brief intervention involving a discontinuation letter found that maintaining 
benzodiazepine discontinuation for the first two years post-intervention was a significant 
predictor of sustaining that change in behaviour ten years later (74). 
The risk of bias assessments highlighted a number of issues with the design of included studies 
which affected their internal validity. Therefore, the pooled effect estimates should be 
interpreted cautiously. These assessments are not directly comparable to previous reviews (29-
31) because different methods were used to assess study quality (e.g. quality scales). One key 
limitation with the older studies which was not raised in previous reviews was the potential for 
contamination whereby patients randomised to intervention and control arms were attending 
the same practice or healthcare professional. To overcome this, future studies would benefit 
from appropriate cRCT designs.  
Given the identified lack of theory underpinning the interventions, application of the TDF 
helped provide insight into mediators of long-term BZRA use that may have been targeted. For 
example, ‘Knowledge’, ‘Skills’ and ‘Beliefs about consequences’ were frequently coded 
suggesting that study authors believed that educating patients about the risks associated with 
long-term BZRA use and providing them with appropriate skills to undertake GDR were 
important in changing their existing behaviour. These are potentially important domains to 
target, as a lack of knowledge and concern about the risks associated with these medications 
have previously been identified as reasons for long-term BZRA use (75). The TDF coding also 
highlighted domains such as ‘Optimism’, ‘Emotion’ and ‘Beliefs about capabilities’ which 
were infrequently coded or not coded at all. Previous qualitative research has reported negative 
patient emotions and perceptions towards discontinuation of long-term BZRA use (75). 
Appropriate targeting of these domains may help to address important patient-level barriers, 
thereby facilitating optimisation of interventions aimed at discontinuation of long-term BZRA 
use.  
Application of the BCTTv1 (44) helped in identifying the interventions’ potential active 
components. ‘Information about health consequences’ was the only BCT that was common 
across all interventions. This is consistent with the ‘Beliefs about consequences’ domain being 
commonly identified across the interventions as per the results of a previous mapping exercise 
linking BCTs to TDF domains (76). Only three interventions included ‘Problem solving’ which 
may be important to consider for inclusion in future interventions as patients have reported 
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barriers to discontinuing long-term BZRA use (e.g. experience of withdrawal symptoms) for 
which solutions could be generated (77). However, further prospective studies of interventions 
involving clearly specified BCTs are needed to identify which BCTs are most effective in 
discontinuing long-term BZRA use. For example, it remains to be seen whether providing 
patients with detailed GDR plans with specified increments of when and how to reduce their 
current dose (coded as ‘Graded tasks’) is more effective than simply providing general 
information on GDR (coded as ‘Instruction on how to perform the behaviour’).  
Given the differences in the results of the TDF and BCT coding exercises across the 
interventions, it is difficult to speculate as to which domains and BCTs were critical to the 
interventions’ effects. The additional exploratory analyses demonstrated a lack of detectable 
relationship between intervention effect size and the results of both of these coding exercises. 
A more detailed exploratory analysis involving meta-regression was not possible due to the 
relatively small number of included studies (66). However, another systematic review that 
conducted a similar TDF coding exercise identified an inverse relationship (40) which suggests 
that targeting multiple domains may not necessarily result in more effective interventions. 
Instead, specific domains should be targeted that are relevant to both the target population and 
behaviour (39, 40). Further research into the most effective BCTs to use in brief interventions 
targeting long-term BZRA use will help to optimise already effective interventions. Describing 
intervention components using the BCTTv1 (44) could enhance transparency of reporting, 
thereby ensuring that interventions can be replicated and applied in other settings. 
This review provides a comprehensive overview of existing evidence for brief interventions 
targeting long-term BZRA use in primary care and includes more studies than any previous 
review. The application of the WIDER checklist (55), together with the intervention coding 
involving the TDF (41) and BCTTv1 (44) represent novel aspects of the review that have 
provided additional insights into intervention content, development and reporting that have, to 
date, been lacking. The limitations of this review were that it focused on studies published in 
the English language and it did not include grey literature.  
 
Conclusion 
This review shows that brief interventions delivered in primary care were more effective than 
usual care in reducing and discontinuing long-term BZRA use. By retrospectively coding the 
interventions using the TDF and BCTTv1, it has been possible to identify key domains targeted 
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by the interventions and the component BCTs. The review findings may help to optimise the 
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Table 1 Overview of included studies  
Study ID 
and location 
Design  Participants 
and setting    
Follow up   Intervention and control group descriptions  Primary review outcomes  



















Intervention (n=51): During a consultation, GPs 
highlighted the risks associated with benzodiazepine 
use and advised patients to reduce and then stop the 
medication. Patients were provided with a self-help 
booklet and encouraged to follow the advice within it. 
The booklet included basic information about 
benzodiazepines and practical advice on stopping, 
including techniques on coping with fears and 
anxieties. 
 
Control (n=58): No intervention received. 
Reduction in 
benzodiazepine use 
(defined as stopping or 





(defined as discontinuation 






















Intervention Group 1 [Letter group] (n=65): 
Patients received a letter from their GP asking them to 
reduce or stop their benzodiazepine use and advising 
that this should be done gradually. 
Intervention Group 2 [Letter plus information 
sheets] (n=75): Patients received the same letter as 
Intervention Group 1, followed at monthly intervals by 
four information sheets giving advice about reducing 
benzodiazepines, including practical suggestions for 
coping without benzodiazepines. 
Control (n=69): No intervention received. 
Reduction in 
benzodiazepine use 
(defined as reduction to half 
or less of original 




(defined as no 
benzodiazepine 
prescriptions after the 
intervention). 





















Intervention Group 1 [Consultation group](n=98): 
Patients were sent a letter inviting them to see their GP 
for a medication review. Guidelines were produced on 
information that should be provided to patients which 
included information about benzodiazepines, reasons 
why it might be beneficial to reduce the medication and 
a timetable that could be used to plan dosage reduction. 
Patients also received a self-help booklet on 
benzodiazepine discontinuation and a leaflet on 
sleeping problems. 
Intervention Group 2 [Letter group] (n=93): 
Patients were sent a letter by their GP which advised 
them to consider reducing or stopping benzodiazepines 
and that this should be done gradually. Patients in this 
group were not sent the self-help booklet or leaflet. 
Control (n=93): Patients received usual care.  
Reduction in 
benzodiazepine use 
(defined as reduction in 




(defined as stopping 
benzodiazepine use). 
 







149 patients who 
were members of 
an integrated 
healthcare 
delivery system  
 
66.4% female 






Intervention Group 1 [Educational intervention] 
(n=50): Patients received a letter from their prescriber 
encouraging them to reconsider their Z-drug use. This 
was supplemented by an educational brochure which 
presented evidence on the risks of Z-drug use together 
with suggestions for other treatment options 
(pharmacological and non-pharmacological) and a 
tapering schedule. A self-assessment quiz on the risks 
of Z-drug use was also included which reinforced 
information in the brochure.  
Intervention Group 2 [Educational intervention and 
follow-up phone call] (n=49): Patients received the 
same intervention as Group 1 which was supplemented 
by a telephone call from a clinical pharmacist 2 to 4 
weeks later. During the call, the pharmacist discussed 
and reinforced information from the educational 
mailing, assessed barriers to Z-drug discontinuation 
and provided advice on tapering, alternatives to Z-
drugs and recommendations for care co-ordination 
through other specialties (e.g. sleep medicine). The 
pharmacist had prescriber approval to implement a 
protocol to switch patients to alternative sleep 
medications. 
Control (n=50): Patients received usual care 
Discontinuation of Z-drug 
use (defined as no Z-drug 
dispensing during the 6-
month follow-up period)  
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Study ID 
and location 
Design  Participants 
and setting    
Follow up   Intervention and control group descriptions  Primary review outcomes  







346 patients who 











Intervention (173): Patients received a letter from a 
clinical pharmacist highlighting the risks of long-term 
alprazolam use. Patients were advised to call the 
clinical pharmacist to discuss reducing alprazolam and 
other potential treatment options. Patients were advised 
not to stop alprazolam prior to consulting the clinical 
pharmacist. The pharmacist collaborated with patients’ 
primary care physician in developing individualised 
gradual dosage reduction plans for patients. The 
pharmacist monitored patients’ progress through 
follow-up phone calls. 
Control (173): Patients received usual care 
Discontinuation of 
alprazolam use  (defined as 
no alprazolam dispensing at 
any time during the six-
month follow-up) 
Reduction of alprazolam 
use  (defined as ≥50% dose 


























Intervention (n=148): A personalised educational 
booklet was mailed to patients. The booklet contained a 
self-assessment detailing risks of benzodiazepine use 
and knowledge statements designed to create cognitive 
dissonance about the perceived safety of 
benzodiazepine use. A peer champion story was also 
included that was designed to encourage participants to 
attempt discontinuation using the included gradual 
dosage reduction protocol.   
Control (n=155): Received usual care and then 
received educational intervention six months after the 
intervention group.  
Reduction in 
benzodiazepine use  
(defined as ≥25% reduction 
in benzodiazepine dose 
compared with baseline and 




(defined as an absence of 
any benzodiazepine 
prescription renewal at the 
time of the 6-month follow-
up that was sustained for ≥3 
consecutive months) 
 




















Intervention (n=73): Patients received a consultation 
from their GP with a standardised message on 
benzodiazepines, covering risks of long-term use and 
information on discontinuing benzodiazepines. Patients 
underwent a 10-25% dosage reduction every 2 weeks 
at follow-up visits. 
Control (n=66):  Patients did not receive the structured 
intervention. Patients were managed according to usual 




(defined as ≥ 50% reduction 





(defined as no 
benzodiazepine use or using 
benzodiazepines no more 
than once every 15 days). 


















6, 12 and 36 
months’ post 
intervention 
Intervention Group 1 [Structured educational 
intervention with follow-up consultation] (n=191): 
During a consultation, GPs provided information on 
the risks of long-term benzodiazepine/Z-drug use and 
reassurance about reducing the medication. A self-help 
leaflet for improving sleep quality was provided to 
patients with insomnia. Patients underwent gradual 
dosage reduction at follow up consultations (10-25% 
reduction every 2-3 weeks). GPs could switch patients 
suffering from withdrawal symptoms to longer acting 
benzodiazepines to aid dosage reduction process. 
Intervention Group 2 [Structured education 
interventions with written follow-up] (n=168): 
Patients received the same initial GP consultation as 
intervention Group 1. They were then provided with 
written instructions reinforcing educational information 
they received together with a tailored gradual dosage 
reduction plan. No follow-up visits were scheduled. 
However, patients could request an appointment with 
their GP when needed. 
Control (n=173): Patients received routine care.  
Discontinuation of 
benzodiazepine use 
(defined as no 
benzodiazepine use or using 
less than four doses of 
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Table 2 Workgroup for intervention development and evaluation research (WIDER) checklist 
assessments 





























 Detailed description provided?  
Characteristics of 
those delivering the 
intervention 
No Yes No Unclear Yes Unclear No Unclear  
Characteristics of 
the recipients 
Unclear Yes Yes Yes Yes Yes Yes Yes 
The setting (e.g., 
worksite, time and 
place of 
intervention) 
Unclear Unclear Yes Unclear Unclear Unclear Yes Unclear  
The mode of 
delivery (e.g., face-
to-face)  
Unclear Yes Yes Yes Yes Yes Unclear Yes 
The intensity (e.g., 
contact time)  
No Unclear Unclear Yes Yes Unclear Unclear No 
The duration (e.g., 
number of sessions 
and their spacing 
over a given period) 
No Unclear Unclear Yes Yes Unclear No No 
Adherence/ fidelity 
to delivery protocols  
No No Unclear Unclear No Unclear No No 
Detailed description 
of the intervention 
content provided for 
each study group  
Unclear Unclear Yes Yes Yes Yes No Unclear 

















et al. 2014  
Kuntz et 
al. 2018  
Navy et 
al. 2018  




No Unclear No Unclear No Yes Unclear  No 
Description of the 
change techniques 
No No No No Unclear Yes No No 
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used in the 
intervention   
Description of the 
causal processes 
targeted by these 
change techniques  
No No No No No Unclear No No 

















et al. 2014  
Kuntz et 
al. 2018  
Navy et 
al. 2018  
 Detailed description provided?  
Has the intervention 
protocol been 
published?  
No No No No Yes Yes No  No 
Is a manual 
describing the 
intervention 
available?    
Unclear No Unclear No No Yes No Unclear 

















et al. 2014  
Kuntz et 
al. 2018  
Navy et 
al. 2018  
 Detailed description provided?  
Details provided of 
the content of active 
control group? (i.e. 
what did usual care 
involve?) 
No No Unclear Unclear Unclear No 
 
No No 
Is a similar level of 
description of the 
content active 
control group 
provided to that of 
the intervention 
itself? 
No No No No No No No No 
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Table 3 Results of Theoretical Domains Framework (TDF) coding 
TDF domains  Identified domains  
 Cormack et 
al. 1994 (62) 
 







al. 2004 (50) 
 
3-armed trial  
Vicens et al. 
2006 (63) 
 
2-armed trial  
Vicens et al. 
2014 (67) 
 
3-armed trial  
Tannenbaum et 
al. 2014 (66)  
 
2-armed trial  










Knowledge CG Unclear  Unclear  Unclear  Yes Yes Unclear  Unclear  Unclear  
IG1 Yes Yes Yes Yes Yes Yes Yes Yes 
IG2 Yes n/a Yes n/a Yes n/a Yes n/a 
Skills  CG Unclear  Unclear  Unclear  Unclear  Unclear  Unclear Unclear Unclear 
IG1 Yes Yes Yes Yes Yes Yes Yes No 
IG2 Yes n/a Yes n/a Yes n/a Yes n/a 
Social/ Professional role 
and identity  
CG Unclear Unclear Unclear Unclear  Unclear Unclear Unclear  Unclear  
IG1 No No No No No No No No 
IG2 No n/a No n/a No n/a No n/a 
Beliefs about capabilities  CG Unclear  Unclear Unclear Unclear Unclear  Unclear Unclear  Unclear  
IG1 No No Yes No No Yes No No 
IG2 No n/a No n/a No n/a No n/a 
Optimism  CG Unclear Unclear  Unclear Unclear Unclear Unclear Unclear  Unclear  
IG1 No No Yes No No Yes No No 
IG2 No n/a Yes n/a No n/a No n/a 
Beliefs about 
consequences 
CG Unclear Unclear  Unclear Yes Unclear  Unclear Unclear  Unclear  
IG1 Yes Yes Yes Yes Yes Yes No Yes 
IG2 Yes 
 
n/a Yes n/a Yes n/a No n/a 
Reinforcement CG Unclear Unclear  Unclear Unclear  Unclear Unclear Unclear  Unclear  
IG1 Yes No Yes Yes Yes No Yes Yes 
IG2 Yes n/a Yes n/a Yes n/a Yes n/a 
Intentions  CG Unclear Unclear  Unclear Unclear Unclear Unclear Unclear  Unclear  
IG1 Yes No No No No No No No 
IG2 Yes n/a Yes n/a No n/a No n/a 
Goals  CG Unclear Unclear  Unclear Unclear Unclear Unclear Unclear  Unclear  
IG1 Yes No No Yes Yes No No No 
IG2 Yes n/a Yes n/a Yes n/a No n/a 
Memory, attention and 
decision Process  
CG Unclear  Unclear  Unclear Unclear  Unclear Unclear  Unclear  Unclear  
IG1 Yes Yes Yes Yes Yes Yes Yes Yes 
IG2 Yes n/a Yes n/a Yes n/a Yes n/a 
Environmental context 
and resources  
CG Unclear Unclear  Unclear Unclear  Unclear Unclear Unclear  Unclear  
IG1 Yes Yes Yes Yes Yes Yes Yes Yes 
IG2 Yes n/a Yes n/a Yes n/a Yes n/a 
Social influences  CG Unclear Unclear  Unclear Unclear Unclear Unclear Unclear  Unclear  
IG1 Yes Yes Yes Yes Yes Yes Yes Yes 
IG2 Yes n/a Yes n/a Yes n/a Yes n/a 
Emotion CG Unclear Unclear  Unclear Unclear Unclear  Unclear Unclear  Unclear  
IG1 No No No No No No No No 
IG2 No n/a No n/a No n/a No n/a 
Behavioural regulation CG Unclear Unclear  Unclear Unclear  Unclear Unclear Unclear  Unclear 
IG1 Yes Yes Yes Yes Yes Yes No Yes 
IG2 Yes n/a Yes n/a Yes n/a Yes n/a 
TDF coding  
Total number of 
different domains 
identified  
CG 0 0 0 2 1 0 0 0 
IG1 10 7 10 9 9 9 6 7 
IG2 10 n/a 11 n/a 9 n/a 7 n/a 
Key: CG= control group, IG1 = Intervention Group 1, IG2= Intervention Group 2  
n/a= not applicable if the study only had one intervention group 
Cormack 1994 – IG1= Letter group, IG2= Letter plus information sheet  
Heather 2004 – IG1= Consultation group, IG2 = Letter group 
Vicens 2014 – IG1=Structured Education Intervention with follow up consultations, 
IG2=Structured Educational Intervention with written follow up 
Kuntz 2018 – IG1 = Educational intervention, IG2 = Education intervention plus pharmacist 
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Table 4 Relationship between intervention effect size and number of different domains 
identified from the Theoretical Domains Framework  




correlation value  
P-value  
Discontinuation at 6 
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Table 5 Behaviour change techniques (BCTs) identified in intervention groups 






















































IG1 No No Yes No Yes Yes  No No 
IG2 Yes n/a No n/a Yes n/a No n/a 
1.3 Goal setting 
(outcome) 
IG1 Yes Yes No No  No No No No 
IG2 Yes n/a Yes n/a No n/a No n/a 
1.4 Action 
planning  
IG1 Yes No No No No No No No 
IG2 Yes n/a No n/a No n/a No n/a 
3.1 Social support 
(unspecified) 
IG1 Yes No No No No Yes  No No 
IG2 Yes n/a Yes n/a Yes n/a No n/a 
3.2 Social support 
(practical) 
IG1 No No No No Yes No No Yes 
IG2 No n/a No n/a No n/a Yes n/a 
4.1 Instruction on 
how to perform the 
behaviour 
IG1 Yes Yes No No No No Yes Yes 




IG1 Yes Yes Yes Yes Yes Yes  Yes Yes 




IG1 No No Yes No No No No No 





No No No No 
 
Yes No No 
IG2 No n/a No n/a No n/a No n/a 
8.7 Graded tasks IG1 No No Yes Yes Yes Yes No No 
IG2 No n/a Yes n/a Yes n/a No n/a 
9.1 Credible source  IG1 Yes Yes Yes Yes Yes No Yes Yes 
IG2 Yes  n/a Yes n/a Yes n/a Yes n/a 
10.4 Social reward IG1 No No No Yes No No No No 




IG1 No No No No Yes No No Yes 
IG2 No n/a No n/a Yes n/a Yes n/a 
11.2 Reduce 
negative emotions 
IG1 No Yes  No No No 
 
No No No 
IG2 No n/a No n/a No n/a No n/a 
12.5 Adding 
objects to the 
environment  
IG1 Yes No No No No Yes Yes Yes 
IG2 Yes n/a Yes n/a No n/a Yes n/a 
13.3 Incompatible 
beliefs 
IG1 No No No Yes No No No No 
IG2  No n/a No n/a No n/a No n/a 
15.3 Focus on past 
success 
IG1 No No No No  Yes No No  No 
IG2 No  n/a No n/a No  n/a No n/a 
BCT identification  
Number of 
different BCTs per 
intervention 
IG1 7 5 5 5 7 6 4 6 
IG2 8 n/a 6 n/a 6 n/a 6 n/a 
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Table 6 Relationship between intervention effect size and number of different BCTs identified 






Discontinuation at 6 
months’ follow-up 
8 -0.551 0.157 
Reduction at 6 months’ 
follow-up 











































Figure 1: PRISMA flow diagram 
 
Records identified through 
database searching  





























Additional records identified 
through other sources  
(n = 1) 
Records after duplicates removed  
(n = 783) 
Records screened  
(n = 783) 
Records excluded  
(n = 722) 
Full-text articles 
assessed for eligibility  
(n = 61) 
Full-text articles excluded, with 
reasons (n=53) 
Study design (n=22); Primary 
outcome not assessed (n=14); Not 
published in English language 
(n=6); Not based in primary care 
(n=3); Not assessing effectiveness 
of a brief intervention (n=1); 
Intervention not solely targeting 
BZRA use (n=2); Conference 
abstract (n=5) 
Studies included in 
qualitative synthesis  
(n = 8) 
Studies included in 
quantitative synthesis 
(meta-analysis)  
(n = 8) 
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Figure 3 Discontinuation of benzodiazepine/Z-drug use at 12 months’ post-intervention 
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Figure 5 Risk of bias assessment of included studies. 
